ZYVERSA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures of 3.05 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures · last filed 2026-03-31
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2025-12-31 was 0.00 shares.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2025-09-30 was 100.00 shares.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2024-12-31 was 0.00 shares.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2024-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2025 was 3.05K shares, a 1243.61% increase from fiscal 2024.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2024 was 227.00 shares, a 97.60% decline from fiscal 2023.
- ZYVERSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2023 was 9.45K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 100.00 shares derived: sum of 2 quarters · filed 2026-03-31 | 3.05K shares 10-K · filed 2026-03-31 | |
| 2025-09-30 | 100.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | 3.05K shares 10-Q · filed 2025-11-19 | ||
| 2025-06-30 | 2.95K shares 10-Q · filed 2025-08-13 | |||
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 0.00 shares derived: sum of 2 quarters · filed 2025-03-27 | 227.00 shares 10-K · filed 2025-03-27 | |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 227.00 shares 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | 227.00 shares 10-Q · filed 2024-08-09 | |||
| 2023-12-31 | -88.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | 5.78K shares derived: sum of 2 quarters · filed 2024-03-25 | 9.45K shares 10-K · filed 2024-03-25 | |
| 2023-09-30 | 94.12K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 97.78K shares 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | 3.67K shares 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |